English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

In recent years, biologics have been widely administered for treating rheumatoid arthritis (RA): however, the safety of these drugs has not been adequately established in embryos and fetuses. We report the case of a pregnant RA patient treated with etanercept, an anti-tumor necrosis factor (TNF) agent. She continued to receive etanercept treatment after becoming pregnant without any complications, finally giving successful birth to a baby girl at 39 weeks. This suggests that etanercept may be selected to treat RA patients with active arthritis who desire pregnancy with lower risks.

A Patient with Rheumatoid Arthritis Who Had a Normal Delivery under Etanercept Treatment